Synapticon: Investment in the Future of Robotics

November 5, 2012

By investing in Synapticon GmbH, Gruibingen, a group of investors consisting of High-Tech Gründerfonds (HTGF), Seedfonds Baden-Wuerttemberg (SFBW), and the private investor Günter Lang is supporting a company in the growing market of robotics. The Synapticon GmbH team has already made a name for itself as a developer of high performance, autonomous robotics systems. With the products DYNARC and OBLAC, Synapticon GmbH is now introducing a hardware and software platform to the market that can be used to realize complex sensor-actuator systems (cyber-physical systems) significantly faster, more reliably and more cost effectively than in the past.

With its DYNARC platform, Synapticon is solving some of the major current problems preventing increased use of service robots in the industry, as well as the realization of products for consumer markets. Instead of having to redevelop electronics and software for robots individually and completely from scratch, Synapticon’s clients can use complete electronic modules including many driver routines that can be configured flexibly based on the respective task. Nikolai Ensslen, Managing Director of Synapticon GmbH, explains the customer benefit as follows: „Synapticon helps shorten development time, reduces risks associated with costs, and makes development processes more competitive.”

The DYNARC platform provides electronic modules that can be combined flexibly and that take over sensor-actuator controlling, regulation, calculations and internal communication as a network within robots. OBLAC is a web-enabled software development environment that completes the Synapticon „toolkit“ for building robotics systems, machines and plants in Industry 4.0.

„The investment as well as the value add of HTGF, the private investor and entrepreneur Günter Lang, and the SFBW allow Synapticon to drive our development services as well as the development and market launch of our own platform“, says Ensslen. „We will use the investment to set up and expand our technical customer support and to increase our service capacity. Furthermore, we will implement the recently initiated serial production of our hardware products.“

Günter Lang is convinced: „The special appeal, but at the same time the challenge of Synapticon is to be able to provide comprehensive engineering beyond the mere development of hardware and software. This makes it possible to not only offer the client products, but to also complete their tasks in a holistic and integrated manner if necessary. What made me commit to Synapticon is that I trust the highly motivated team with its broad knowledge to handle the resulting challenges.“

HTGF is also optimistic about the cooperation. Investment Manager Benjamin Erhart adds: „We are convinced that the company has significant growth potential due to its know-how and the exciting market environment. We are happy to support this talented team as it enters the market.“

Steffen Gasior, Investment Manager at MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg GmbH says about the investment: „With its unique networking technologies for complex automation processes, Synapticon GmbH is targeting a highly attractive future market. The benefit for users is clear: Allowing the manufacturers of complex products, machines and systems to simplify and accelerate their development processes. We see significant potential for development based on a dynamic founding team and a promising product pipeline.“

About Synapticon GmbH
Synapticon is a young, international company headquartered in Gruibingen, Baden-Wuerttemberg that is tackling the task of improving future robotics and automation technology with innovative embedded systems. Synapticon’s DYNARC distributed computing technology combines modular embedded hardware, model-based software development, and a complete development environment in order to allow manufacturers of complex products, machines, and systems to simplify and accelerate their development processes. Synapticon also provides development services.
Visit for more information.

Synapticon GmbH
Nikolai Ensslen
Hohlbachweg 2
73344 Gruibingen
Phone: +49 7335 186999-0

About MBG
MBG invests in small and medium sized companies across different industries headquartered in Baden-Wuerttemberg. The amounts invested range from €25,000 up to €2,5 million. MBG offers everything from seed investments to start-up financing all the way to growth financing for established companies.

MBG is a publicly funded holding company. It works closely with the guarantor bank Bürgschaftsbank Baden-Wuerttemberg GmbH and is supported by the State of Baden-Württemberg and by the Federal Government. It is therefore able to offer attractive conditions.

About Seedfonds BW
Seedfonds BW cooperates with High-Tech Gründerfonds to support young technology companies headquartered in Baden-Wuerttemberg during the early founding or seed phase by providing venture capital. In addition to the State of Baden-Wuerttemberg (Ministry of Finance and Economy) , the investors of Seedfonds BW are the L-Bank, LBBW Venture Capital GmbH and  MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg GmbH.

MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg GmbH
Steffen Gasior
Investment Manager
Werastraße 15-17
70182 Stuttgart
Phone: +49 0711 1645-773
Fax: +49 0711 1645-8773

About Günter Lang
Günter Lang is an engineer and experienced entrepreneur in the field of engineering and automation for the process and manufacturing industry. His investment activities are focused on the technology sector and on high-quality technical services.

Günter Lang
Gräfensteinstraße 3
D-67434 Neustadt an der Weinstraße
Phone: +49 (0) 6321 / 963868

About High-Tech Gründerfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as fourteen industrial groups of ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 565,5 million under management in two funds (EUR 272 million HTGF I, EUR 293,5 million HTGF II).

High-Tech Gründerfonds Management GmbH
Benjamin Erhart
Investment Manager
Schlegelstraße 2
53113 Bonn
Phone: +49 228 823 00 100
Fax: +49 228 823 00 050

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

10. July 2024

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today announced the closing of a Series C rou
9. July 2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.

The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Pa